Therapy News and Research

RSS

Exenatide ‑ a better alternative for add-on therapy?

Twice-daily exenatide may offer advantages over the standard glimepiride in patients with Type 2 diabetes inadequately controlled by metformin, suggest findings published in The Lancet.

19 Jun 2012

HCV suppression reduces liver damage

Profound suppression of the hepatitis C virus reduces long-term hepatic inflammation and fibrosis even in patients who do not achieve a sustained virologic response, research demonstrates.

19 Jun 2012

First Edition: June 19, 2012

Today's headlines include more speculation about the political implications of the Supreme Court's much-anticipated health law decision.

19 Jun 2012

SomnoMed and Sleep HealthCenters partner to create National Center for Integrated Dental Sleep Health

SomnoMed and Sleep HealthCenters are pleased to announce a partnership to create the National Center for Integrated Dental Sleep Health (NCIDSH) program.

19 Jun 2012

ASI completes $5.3 million Series A Preferred Stock financing

Ablative Solutions, Inc. (ASI), a privately-held company headquartered in Kalamazoo, MI with offices in Menlo Park, CA announced today that it has completed a Series A Preferred Stock financing, totaling approximately $5.3 million (including the conversion of the bridge financing completed earlier this year), to fund its unique technology platform.

19 Jun 2012

Multi-modal approach reduces pain and side effects of medication following joint replacement surgery

Reducing acute post-surgical pain and side effects of medications for patients undergoing knee and hip replacement surgery is the focus of a new multi-modal approach at Greenwich Hospital in Greenwich, Connecticut.

19 Jun 2012

New patent filed for VAC-3S, an immunotherapy for treating HIV infections

InnaVirVax, a biopharmaceutical company specialized in the research and development of therapeutic and diagnostic innovations focused on immune dysregulation, announced today that a new European patent application has been filed on VAC-3S, a “first-in-class” immunotherapy for the treatment of HIV infections.

19 Jun 2012

Colectomy need in patients with severe ulcerative colitis drastically reduced by Kappaproct

InDex Pharmaceuticals today announced the publication of positive data from the Company's compassionate use program with its lead compound Kappaproct.

19 Jun 2012

Antiarrhythmic short-term treatment useful for some patients

Atrial fibrillation (AF) is the most frequently sustained arrhythmia of the heart. It affects several million people in Europe. AF causes a loss of contraction in the atria and gives rise to heart failure. Moreover, it is associated with a high risk of stroke. One in five strokes is due to AF.

19 Jun 2012

Single-dose vaccine for treatment of cocaine addiction

A single-dose vaccine capable of providing immunity against the effects of cocaine offers a novel and groundbreaking strategy for treating cocaine addiction is described in an article published Instant Online in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc.

19 Jun 2012

Implanted device delivers genetically engineered neurotrophic factor directly to the brain

Studies suggest that neurotrophic factors, which play a role in the development and survival of neurons, have significant therapeutic and restorative potential for neurologic diseases such as Huntington's disease. However, clinical applications are limited because these proteins cannot easily cross the blood brain barrier, have a short half-life, and cause serious side effects.

19 Jun 2012

Five abstracts evaluating Abbott's LCIG presented at Parkinson's disease congress

Today Abbott announced results from five abstracts evaluating levodopa-carbidopa intestinal gel (LCIG), its investigational compound for advanced Parkinson's disease.

19 Jun 2012

New clinical data for ZEVALIN Injection for intravenous use presented at 17th EHA Congress

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced new clinical data presented in an oral presentation for ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use at the 17th Congress of the European Hematology Association (EHA).

19 Jun 2012

Rusk Rehabilitation moves to NYU Langone's new Ambulatory Care Center

NYU Langone Medical Center announced that Rusk Rehabilitation non-musculoskeletal outpatient rehabilitation care, research and administrative offices have moved to a 40,000 square-foot space in NYU Langone's new Ambulatory Care Center (ACC) located at 240 East 38th Street in Manhattan.

19 Jun 2012

Global market for wound closures to grow at 4.3% CAGR to reach $15.2 billion in 2016

As the worldwide economy recovers from recession into a new period of growth there is little doubt these developments will have a positive effect on the healthcare technologies market, including the multi-billion dollar Wound Management segment.

18 Jun 2012

BEAMing DNA blood testing technology detects drug resistance in colorectal cancer patients early

Two studies published back-to-back in last week's Nature applied DNA blood testing using the BEAMing technology to detect drug resistance mediated by KRAS mutations in colorectal cancer patients months before treatment failure was observed.

18 Jun 2012

CINJ commences enrollment in three-drug combination trial for breast cancer

Researchers at The Cancer Institute of New Jersey (CINJ) are enrolling patients for a clinical trial, which aims to evaluate a new drug for breast cancer that has spread (metastatic) in combination with two chemotherapy agents called doxorubicin and cyclophosphamide.

18 Jun 2012

Dehaier, Heyer enter into three-year strategic mutual cooperation agreement

Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that the Company has entered into a three-year strategic mutual cooperation agreement with HEYER Medical AG, an internationally recognized, Germany-based company specializing in state-of-the-art inhalation and anesthesia equipment, oxygen concentrators, breathing therapy equipment and connecting equipment.

18 Jun 2012

Cancer publishes Aeterna Zentaris' perifosine Phase 2 trials in RCC

Aeterna Zentaris Inc. today announced that data from two Phase 2 trials in renal cell carcinoma (RCC) for the Company's oral anticancer drug, perifosine, have been published in the June 2012 issue of Cancer, a publication of the American Cancer Society.

18 Jun 2012

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from the pivotal PACE trial of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with chronic myeloid leukaemia (CML) or Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL), who are resistant or intolerant to dasatinib or nilotinib or who have the T315I mutation.

18 Jun 2012

Therapy News and Research

Exenatide ‑ a better alternative for add-on therapy?

HCV suppression reduces liver damage

First Edition: June 19, 2012

SomnoMed and Sleep HealthCenters partner to create National Center for Integrated Dental Sleep Health

ASI completes $5.3 million Series A Preferred Stock financing

Multi-modal approach reduces pain and side effects of medication following joint replacement surgery

New patent filed for VAC-3S, an immunotherapy for treating HIV infections

Colectomy need in patients with severe ulcerative colitis drastically reduced by Kappaproct

Antiarrhythmic short-term treatment useful for some patients

Single-dose vaccine for treatment of cocaine addiction

Implanted device delivers genetically engineered neurotrophic factor directly to the brain

Five abstracts evaluating Abbott's LCIG presented at Parkinson's disease congress

New clinical data for ZEVALIN Injection for intravenous use presented at 17th EHA Congress

Rusk Rehabilitation moves to NYU Langone's new Ambulatory Care Center

Global market for wound closures to grow at 4.3% CAGR to reach $15.2 billion in 2016

BEAMing DNA blood testing technology detects drug resistance in colorectal cancer patients early

CINJ commences enrollment in three-drug combination trial for breast cancer

Dehaier, Heyer enter into three-year strategic mutual cooperation agreement

Cancer publishes Aeterna Zentaris' perifosine Phase 2 trials in RCC

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News